VMAT2 inhibitor - Neurocrine Biosciences
Latest Information Update: 28 Dec 2021
At a glance
- Originator Neurocrine Biosciences
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Psychiatric disorders
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Neurological-disorders(In volunteers) in USA
- 28 Dec 2021 No recent reports of development identified for phase-I development in Psychiatric-disorders(In volunteers) in USA
- 05 Nov 2018 Phase-I clinical trials in Neurological disorders (In volunteers) in USA (unspecified route) before November 2018